NCT05970822 - Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions

Myelodysplastic SyndromesChronic Myelomonocytic Leukemia

Interventions

DRUG

BC3402

Escalating of BC3402 will be administered IV(intravenous)

DRUG

Azacitidine

Azacitidine will be administered daily

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin